Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06380660
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2024-04-16
Brief Title:
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Sponsor:
Acerand Therapeutics Shanghai Limited
Organization:
Acerand Therapeutics Limited
Study Overview
Official Title:
A Phase III Open-label Multicentre Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase PARP inhibitor ACE-86225106 is safe tolerable and has anti-cancer activity in adult patients with advanced solid tumors
Detailed Description:
This study is a Phase III open-label multicentre study of ACE-86225106 administered orally in patients with advanced solid tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None